NasdaqGS:STOKBiotechs
Is Stoke Therapeutics (STOK) A Bargain On Its EMPEROR Trial Enrollment Milestone?
Why Stoke Therapeutics Stock Is Back In Focus After A Key Trial Milestone
Stoke Therapeutics (STOK) is drawing fresh attention after its Phase III EMPEROR trial for Dravet syndrome exceeded its 150 patient enrollment target, reaching 162 participants with no discontinuations reported.
See our latest analysis for Stoke Therapeutics.
At a share price of $32.14, Stoke Therapeutics has seen a 10.64% 1 month share price return and a 73.82% 1 year total shareholder return. These figures suggest...